- This event has passed.
Leadership Series: A New Approach to Alzheimer’s Disease
May 27 @ 6:00 pm - 7:00 pmFree
Speaker: Paul Alan Cox, Ph.D., Biology, Harvard University
The pharmaceutical industry has completed nearly 500 human clinical trials in an attempt to discover a safe and effective treatment for Alzheimer’s disease. Unfortunately, at an aggregate cost of one-half trillion dollars, these trials have failed, with major firms including Pfizer, Lilly, and Merck withdrawing completely from Alzheimer’s research.
The failed trials are based on three key assumptions:
1) Alzheimer’s disease is caused by b-amyloid plaque and misfolded tau neurofibrillary tangles,
2) Alzheimer’s mouse models are adequate preclinical screens for drug candidates, and
3) human clinical trials cost about a billion dollars and take up to a decade to complete.
At the Brain Chemistry Labs, we question all three of these assumptions.